Profiling of drug response mechanisms and patient sub-populations through readouts from a biobank of patient-derived neurons
Collaboration with NeuroKaire: Daphna Laifenfeld PhD, Tal Birnberg PhD, David Pattison, Claudia Albeldas, Elena Kagan
CLE-400: Topical α2-adrenergic agonist being developed as a novel mechanism for treating chronic pruritus associated with Notalgia Paresthetica
Orna Goren, PhD
Introducing CLE-905, a Potent Dual M1/M4 Receptor Agonist in Development for Treatment of Schizophrenia and Additional Psychiatric Disorders
Hadile Ounallah-Saad, PhD
Introducing CLE-400; Topical Alpha-2-Adrenergic Agonist as a First-in-Class Treatment for Localized Chronic Pruritus
Mary Spellman, M.D.
A Phase 2 Randomized Controlled Adjunctive Treatment Trial with CLE-100 Esketamine Tablet for Patients with Major Depressive Disorder and Inadequate Response to Antidepressants, During the COVID-19 Pandemic
Maurizio Fava, Oren Berkowitz, Sanjay J. Mathew, Michael E. Thase, Andrew A. Nierenberg, Dan V. Iosifescu, L. Alison McInnes, Cristina Cusin, Robert Berman, Eli Eyal, Ari Gershon, Esther Lukasiewicz-Hagai
High Unmet Medical Need in Brachioradial Pruritus: Results from a Large Patient Survey
Elinor Artsy Navon, MD
Dysphagia and its Relationship to Medication Intake in Parkinson's Disease
Elijahu Berkovich, PhD and Dorit Mimrod, PhD
OLAR®: A Novel Oral Long Acting Release (OLAR®) platform
Menashe Levy
Sleep problems in Parkinson’s Disease: PD patients’ survey on common issues and treatments expectations
Elijahu Berkovich, PhD
CLE-400 for Chronic Neuropathic Itch
Yael Rosen, MD
CLE-600: Treating nocturnal and early morning OFF symptomology in Parkinson's disease with the OLAR platform Elijahu Berkovich, PhD
Learn MoreCLE 400 a potent alpha 2 adrenergic receptor agonist for the treatment of chronic itch
Elanite Caspi, PhD
CLE-400 a Potent Analgesic Topical Gel in Acute and Chronic Pain Pig Models.
Elanite Caspi, PhD
CLE-400 a potent alpha 2 adrenergic receptor agonist for the treatment of chronic itch
Johanna Schumann, PhD
CLE-600: Treating nocturnal and early morning OFF symptomology in Parkinson’s disease with the OLAR® platform
Elijahu Berkovich, PhD
CLE-400 a novel non-opioid topical treatment for painful diabetic neuropathy
Orna Goren, PhD
Introducing the OLAR platform
Elijahu Berkovich, PhD